S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

$1.44
+0.06 (+4.20%)
(As of 11:06 AM ET)
Today's Range
$1.38
$1.49
50-Day Range
$0.92
$1.38
52-Week Range
$0.47
$1.69
Volume
18,877 shs
Average Volume
45,966 shs
Market Capitalization
$20.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Context Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
177.8% Upside
$4.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Context Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($0.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

688th out of 939 stocks

Pharmaceutical Preparations Industry

317th out of 433 stocks

CNTX stock logo

About Context Therapeutics Stock (NASDAQ:CNTX)

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CNTX Stock Price History

CNTX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Context Therapeutics Inc. (CNTX)
See More Headlines
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+177.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.74 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.28 million
Optionable
Not Optionable
Beta
2.13
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

CNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTX shares.
View CNTX analyst ratings
or view top-rated stocks.

What is Context Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Context Therapeutics' shares. Their CNTX share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts price targets for CNTX
or view top-rated stocks among Wall Street analysts.

How have CNTX shares performed in 2024?

Context Therapeutics' stock was trading at $1.13 at the beginning of 2024. Since then, CNTX stock has increased by 27.4% and is now trading at $1.44.
View the best growth stocks for 2024 here
.

Are investors shorting Context Therapeutics?

Context Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 17,000 shares, an increase of 57.4% from the February 29th total of 10,800 shares. Based on an average daily trading volume, of 56,600 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company's shares are short sold.
View Context Therapeutics' Short Interest
.

When is Context Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CNTX earnings forecast
.

When did Context Therapeutics IPO?

Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

Who are Context Therapeutics' major shareholders?

Context Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Opaleye Management Inc. (6.11%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr.
View institutional ownership trends
.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners